Cargando…

Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery

OBJECTIVES: The postoperative period of cardiac surgery (CS) is associated with the development of major adverse cardiovascular events (MACEs). However, the evaluation of MACE after CS by means of biomarkers is poorly developed. We aimed to evaluate postoperative biomarkers that could be associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Imperiali, Claudia E., Lopez-Delgado, Juan C., Dastis-Arias, Macarena, Sanchez-Navarro, Lourdes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197270/
https://www.ncbi.nlm.nih.gov/pubmed/37360622
http://dx.doi.org/10.1515/almed-2020-0031
_version_ 1785044515056254976
author Imperiali, Claudia E.
Lopez-Delgado, Juan C.
Dastis-Arias, Macarena
Sanchez-Navarro, Lourdes
author_facet Imperiali, Claudia E.
Lopez-Delgado, Juan C.
Dastis-Arias, Macarena
Sanchez-Navarro, Lourdes
author_sort Imperiali, Claudia E.
collection PubMed
description OBJECTIVES: The postoperative period of cardiac surgery (CS) is associated with the development of major adverse cardiovascular events (MACEs). However, the evaluation of MACE after CS by means of biomarkers is poorly developed. We aimed to evaluate postoperative biomarkers that could be associated with MACE. METHODS: Two Hundred and ten patients who underwent CS were enrolled during the study period. The diagnosis of MACE was defined as the presence of at least one of the following complications: acute myocardial infarction, heart failure, stroke presented during intensive care unit (ICU) stay, and 30-day mortality after CS. High-sensitive troponin T (hs-TnT), C-reactive protein, procalcitonin, interleukin-6, and immature platelet fraction (IPF) were measured on ICU admission and after 24 h. The difference between both measurements (Δ) was calculated to assess their association with MACE. Early infected patients (n=13) after CS were excluded from final analysis. RESULTS: The most frequent surgery was single-valve surgery (n=83; 38%), followed by coronary artery bypass graft (n=72; 34%). Postoperative MACE was diagnosed in 31 (14.8%) patients. Biomarker dynamics showed elevated values at 24 h compared with those at ICU admission in patients with MACE versus no-MACE. Multivariate analysis showed that ΔIPF (OR: 1.47; 95% CI: 1.110–1.960; p=0.008) and Δhs-TnT (OR: 1.001; 95% CI: 1.0002–1.001; p=0.008) were independently associated with MACE. CONCLUSIONS: These findings suggest that postoperative ΔIPF and Δhs-TnT may be useful biomarkers for the identification of patients at risk of MACE development.
format Online
Article
Text
id pubmed-10197270
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-101972702023-06-23 Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery Imperiali, Claudia E. Lopez-Delgado, Juan C. Dastis-Arias, Macarena Sanchez-Navarro, Lourdes Adv Lab Med Article OBJECTIVES: The postoperative period of cardiac surgery (CS) is associated with the development of major adverse cardiovascular events (MACEs). However, the evaluation of MACE after CS by means of biomarkers is poorly developed. We aimed to evaluate postoperative biomarkers that could be associated with MACE. METHODS: Two Hundred and ten patients who underwent CS were enrolled during the study period. The diagnosis of MACE was defined as the presence of at least one of the following complications: acute myocardial infarction, heart failure, stroke presented during intensive care unit (ICU) stay, and 30-day mortality after CS. High-sensitive troponin T (hs-TnT), C-reactive protein, procalcitonin, interleukin-6, and immature platelet fraction (IPF) were measured on ICU admission and after 24 h. The difference between both measurements (Δ) was calculated to assess their association with MACE. Early infected patients (n=13) after CS were excluded from final analysis. RESULTS: The most frequent surgery was single-valve surgery (n=83; 38%), followed by coronary artery bypass graft (n=72; 34%). Postoperative MACE was diagnosed in 31 (14.8%) patients. Biomarker dynamics showed elevated values at 24 h compared with those at ICU admission in patients with MACE versus no-MACE. Multivariate analysis showed that ΔIPF (OR: 1.47; 95% CI: 1.110–1.960; p=0.008) and Δhs-TnT (OR: 1.001; 95% CI: 1.0002–1.001; p=0.008) were independently associated with MACE. CONCLUSIONS: These findings suggest that postoperative ΔIPF and Δhs-TnT may be useful biomarkers for the identification of patients at risk of MACE development. De Gruyter 2020-07-27 /pmc/articles/PMC10197270/ /pubmed/37360622 http://dx.doi.org/10.1515/almed-2020-0031 Text en © 2020 Claudia E. Imperiali et al., published by De Gruyter, Berlin/Boston https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Article
Imperiali, Claudia E.
Lopez-Delgado, Juan C.
Dastis-Arias, Macarena
Sanchez-Navarro, Lourdes
Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
title Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
title_full Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
title_fullStr Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
title_full_unstemmed Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
title_short Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
title_sort biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac surgery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197270/
https://www.ncbi.nlm.nih.gov/pubmed/37360622
http://dx.doi.org/10.1515/almed-2020-0031
work_keys_str_mv AT imperialiclaudiae biomakerevaluationformajoradversecardiovasculareventdevelopmentinpatientsundergoingcardiacsurgery
AT lopezdelgadojuanc biomakerevaluationformajoradversecardiovasculareventdevelopmentinpatientsundergoingcardiacsurgery
AT dastisariasmacarena biomakerevaluationformajoradversecardiovasculareventdevelopmentinpatientsundergoingcardiacsurgery
AT sancheznavarrolourdes biomakerevaluationformajoradversecardiovasculareventdevelopmentinpatientsundergoingcardiacsurgery